Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.
about
Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP.Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation.
P2860
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@ast
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@en
type
label
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@ast
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@en
prefLabel
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@ast
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@en
P2093
P2860
P1476
Addition of rituximab is not a ...... diffuse large B-cell lymphoma.
@en
P2093
Changgong Zhang
Jianliang Yang
Liqiang Zhou
Shanshan Chen
P2860
P304
P356
10.3978/J.ISSN.1000-9604.2015.10.04
P577
2015-10-01T00:00:00Z